The DOI matches its Crossref record; 71 of the 75 references it cites were found in a registry or an index.
Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite
Abstract
Bisphosphonates are now the most widely used drugs for diseases associated with increased bone resorption, such as osteoporosis. Although bisphosphonates act directly on osteoclasts, and interfere with specific biochemical processes such as protein prenylation, their ability to adsorb to bone mineral also contributes to their potency and duration of action. The aim of the present study was to compare the binding affinities for hydroxyapatite (HAP) of 6 bisphosphonates currently used clinically and to determine the effects of these bisphosphonates on other mineral surface properties including zeta potential and interfacial tension. Affinity constants (K(L)) for the adsorption of bisphosphonates were calculated from kinetic studies on HAP crystal growth using a constant composition method at 37 degrees C and at physiological ionic strength (0.15 M). Under conditions likely to simulate bisphosphonate binding onto bone, there were significant differences in K(L) among the bisphosphonates for HAP growth (pH 7.4) with a rank order of zoledronate > alendronate > ibandronate > risedronate > etidronate > clodronate. The measurements of zeta potential show that the crystal surface is modified by the adsorption of bisphosphonates in a manner best explained by molecular charges related to the protonation of their side-chain moieties, with risedronate showing substantial differences from alendronate, ibandronate, and zoledronate. The studies of the solid/liquid interfacial properties show additional differences among the bisphosphonates that may influence their mechanisms for binding and inhibiting crystal growth and dissolution. The observed differences in kinetic binding affinities, HAP zeta potentials, and interfacial tension are likely to contribute to the biological properties of the various bisphosphonates. In particular, these binding properties may contribute to differences in uptake and persistence in bone and the reversibility of effects. These properties, therefore, have potential clinical implications that may be important in understanding differences among potent bisphosphonates, such as the apparently more prolonged duration of action of alendronate and zoledronate compared with the more readily reversible effects of etidronate and risedronate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The results show a high tendency of BPs to bone mineralization and especially the return of lost bone volume (Nancollas et al., 2006).”
From Osteogenesis Improvement of Gelatin-Based Nanocomposite Scaffold by Loading Zoledronic Acid (2022) · cites this paper as Nancollas et al., 2006
Citations
Cites
The Dynamics of Capillary Flow
Washburn, E. W. (1921) · Physical Review · doi:10.1103/physrev.17.273 · Cited by 7,202
Zeta Potential in Colloid Science
(1981) · Elsevier eBooks · doi:10.1016/c2013-0-07389-6 · Cited by 2,349
Interfacial Forces in Aqueous Media
van Oss, C. J. (2006) · CRC Press eBooks · doi:10.1201/9781420015768 · Cited by 1,921
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J., Lang, T., Garnero, P., Bouxsein, M., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,168
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Self-citationInterfacial Forces in Aqueous Media
Visser, H. (1995) · Powder Technology · doi:10.1016/0032-5910(95)90005-5 · Cited by 884
Liotta, S. (1965) · Journal of the American Chemical Society · doi:10.1021/ja01084a069 · Cited by 881
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z. D., Richardson, P. A., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 870
Bisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 838
Self-citation
Research works printed but not linked: 9
- Benedict J.J., The physical chemistry of the diphosphonates—Its relationship to their medical activity. In: Donath A., Courvoisier B., editors. Symposium Cemo, Centre D'Etude des Maladies Osteoarticulatires de Geneve (IV), 1–19. 1982. Geneva, Editions Medicine et Hygiene. Diphosphonates and Bone;1990:7–9.
- Sunberg, 1991, Designing drugs for stronger bones, Chemtech, 21, 304
- Ebetino, 1998, Mechanisms of action of etidronate and other bisphosphonates, Rev. Contemp. Pharmacother., 9, 233
- Traube, 1927, Solubility and surface tension, Ber, 60B, 1808
- Semenchenko, 1934, Solubility and surface tension, Uspekhi Khimii, 3, 710
- Bagda, 1978, The relation between surface tension and the solubility parameter in liquids, Farbe Lack, 84, 212
- Leu, 2004, Relative binding affinities of bisphosphonates for human bone, Bone, 34, S62
- Christiansen, 2003, Comparison of risedronate and alendronate pharmacokinetics at clinical doses, Osteoporos Int., 14, S38
- Watts, 2004, Treatment discontinuation effects on bone turnover and BMD with risedronate, Bone, 34, S99
Cited by
Sorted by citations
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,442
Self-citationSambrook, P. N., & Cooper, C. C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,201
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,164
Self-citationShane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
Metadata
- Authors
- Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H.
- Affiliations
- University at Buffalo, State University of New York (US)
- Procter & Gamble (United States) (US)
- Nuffield Orthopaedic Centre (GB)
- Corresponding author
- Ebetino, F.H.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 38
- Issue
- 5
- Pages
- 617-627
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2128778774
- Cited by
- 862
- References
- 75
- Citations by year
- 2026: 17 · 2025: 23 · 2024: 15 · 2023: 24 · 2022: 41 · 2021: 29 · 2020: 45 · 2019: 39 · 2018: 44 · 2017: 40 · 2016: 39 · 2015: 45 · 2014: 55 · 2013: 48 · 2012: 44
- FWCI
- 18.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Bone (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Dental and Craniofacial Research (DE03223)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- bisphosphonates, hydroxyapatite, drug adsorption, binding affinity, crystal growth inhibition, zeta potential, interfacial tension, zoledronic acid, alendronate, ibandronate, risedronate, etidronate, clodronate, bone mineral, osteoporosis, duration of action, protein prenylation
- MeSH terms
- Bone and Bones, Crystallization, Diphosphonates, Humans, Stress, Mechanical, Durapatite, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
